IND Enabling Studies for an Orally Bioavailable Parkinson’s Disease Modifying Molecule


To scale up production of a new Parkinson’s disease drug, assess toxicity, and prepare for clinical trials

Anticipated Impact: 

More effective treatment for Parkinson’s disease


Parkinson’s disease is a devastating condition that destroys neurons. At present, progression of the disease can be slowed, but it is incurable. M3 Biotechnology is testing the ability of its lead compound, MM-201, to restore neurons destroyed in Parkinson’s disease. Promising preliminary data, derived in part from a prior LSDF grant, suggest the compound is safe and effective in animal models. Extensive work to determine toxicity and dosing will be conducted to prepare the compound for an FDA filing, which would allow a human Phase I clinical trial. LSDF funding will be matched at least equally by private investors.

Collaborating organizations: Cerep, MPI Research, Pharmatek Laboratories, RS Synthesis, Xenometrics

Parkinson’s Disease Treatment

Grant Update

Principal Investigator:
Leen Kawas
Grantee Organization:
M3 Biotechnology Inc.
Grant Title:
IND enabling studies for an orally bioavailable Parkinson's disease modifying molecule
Grant Cohort and Year:
2015 Matching (05)
Grant Period:
05/27/2015 - 05/26/2017 (Completed)
Grant Amount:
The LSDF grant has been instrumental to drive the development of our program and lead compound. We currently have a disease modifying therapeutic that is being developed and a few months from first in human clinical trials. he grant helped us manufacture the compound and make enough of it to run our stability and safety studies in preparation for clinical trials.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact

Legislative Districts:
11, 34, 36, 37, 43, 46, 48

Health Impacts

Parkinson's Disease Treatment

Feb 11, 2016
Puget Sound Business Journal
Jan 31, 2016
WSU Magazine
Jan 1, 2016
Washington Business